Discover top 2025 investment insights—why diversified portfolios, US Tech, and European equities outperformed.

Q3 2025 Earnings Call Transcript December 17, 2025 Spire Global, Inc. reports earnings inline with expectations. Reported EPS ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

James Madison completed a 12-1 season by defeating Troy in the championship game to win the Sun Belt conference in Coach ...

Discover why Palo Alto Networks (PANW) is rated BUY after strong Q1 results, AI-focused acquisitions, and a 20% upside.

Clinicians Laura Huppert, Kelsey Natsuhara, and Magdelena Ford discuss the evidence, challenges, and real-world considerations guiding CDK4/6 inhibitor management in the adjuvant setting.

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

Discover the best Application Performance Monitoring (APM) tools that enable enterprises to enhance application performance, ensure seamless digital experiences, and drive long-term growth in 2025.

A dangerous drug gave them a lifetime of disabilities. Hard-won compensation has made difficult days easier and more joyful – but some feel the 2015 support program still falls short ...

MoneyHero Limited Class A Ordinary Shares (NASDAQ: MNY) Q3 2025 Earnings Call Transcript December 5, 2025 MoneyHero Limited Class A Ordinary Shares misses on earnings expectations. Reported EPS is $-0 ...

Extracorporeal membrane oxygenation (ECMO) technology has relative contraindications in haemorrhagic disease but remains an effective therapeutic option for the treatment of pulmonary haemorrhage ...